Skip to main content
Figure 2 | Journal of Translational Medicine

Figure 2

From: Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer

Figure 2

VLC express CD52. A. RT-PCR demonstrating CD52 mRNA expression in VLCs FACS isolated from 4 ovarian tumors (NTC-no template control). B. qRT-PCR quantification of CD52 mRNA expression in FACS-isolated VLC and tumor endothelial cells (TECs). C. FACS analysis confirming CD52 protein expression on CD45+/VE-Cadherin+ VLC. VLC do not express the T cell marker CD4. CD45(-)/VE-Cadherin+ tumor endothelial cells do not express CD52. D. Immunofluorescence demonstrating co-expression of VE-Cadherin (red) and anti-CD52 (green) in ovarian cancer. Arrows indicate CD52+/VE-Cadherin(-) lymphocytes.

Back to article page